Baxter International’s drug candidate Gammagard is the latest Alzheimer’s therapeutic to fail in meeting its clinical endpoints. A number of other potential therapies have suffered similar fates. With these failures in mind, how can Alzheimer’s sufferers remain optimistic that relief is in sight?
Poll Question:
Do you foresee a major breakthrough in the treatment of Alzheimer’s disease within the next 10 years?
Yes
85
No
45
Undecided
16
